Huaren Pharmaceutical Co Ltd (300110) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Huaren Pharmaceutical Co Ltd (300110) has a cash flow conversion efficiency ratio of 0.061x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥86.78 Million ≈ $12.70 Million USD) by net assets (CN¥1.43 Billion ≈ $208.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Huaren Pharmaceutical Co Ltd (300110) market capitalisation for the company's overall valuation and market capitalisation.
Huaren Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Huaren Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Huaren Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Huaren Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore Huaren Pharmaceutical Co Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Synmosa Biopharma
TWO:4114
|
0.018x |
|
Jaguar Mining Inc
TO:JAG
|
0.061x |
|
Malam Team
TA:MLTM
|
-0.062x |
|
Nanjing Zhongbei Group Co Ltd
SHE:000421
|
0.037x |
|
Invesco California Value Muni Inc Tr
NYSE:VCV
|
0.018x |
|
Tianjin Jieqiang Power Equipment Co
SHE:300875
|
-0.007x |
|
KT Submarine Co. Ltd
KQ:060370
|
0.022x |
|
Apex Healthcare Bhd
KLSE:7090
|
0.038x |
Annual Cash Flow Conversion Efficiency for Huaren Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Huaren Pharmaceutical Co Ltd from 2007 to 2025. View Huaren Pharmaceutical Co Ltd (300110) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥909.06 Million ≈ $133.02 Million |
CN¥390.23 Million ≈ $57.10 Million |
0.429x | +82.96% |
| 2024-12-31 | CN¥1.37 Billion ≈ $201.05 Million |
CN¥322.36 Million ≈ $47.17 Million |
0.235x | +112.36% |
| 2023-12-31 | CN¥2.77 Billion ≈ $404.75 Million |
CN¥305.60 Million ≈ $44.72 Million |
0.110x | +31.77% |
| 2022-12-31 | CN¥2.60 Billion ≈ $380.43 Million |
CN¥217.98 Million ≈ $31.90 Million |
0.084x | +135.41% |
| 2021-12-31 | CN¥2.44 Billion ≈ $357.55 Million |
CN¥-578.52 Million ≈ $-84.66 Million |
-0.237x | -5034.78% |
| 2020-12-31 | CN¥2.33 Billion ≈ $340.88 Million |
CN¥-10.74 Million ≈ $-1.57 Million |
-0.005x | -103.35% |
| 2019-12-31 | CN¥2.25 Billion ≈ $329.02 Million |
CN¥309.33 Million ≈ $45.26 Million |
0.138x | +21.89% |
| 2018-12-31 | CN¥2.25 Billion ≈ $329.72 Million |
CN¥254.32 Million ≈ $37.21 Million |
0.113x | -17.22% |
| 2017-12-31 | CN¥1.55 Billion ≈ $226.55 Million |
CN¥211.08 Million ≈ $30.89 Million |
0.136x | +14.53% |
| 2016-12-31 | CN¥1.53 Billion ≈ $223.29 Million |
CN¥181.65 Million ≈ $26.58 Million |
0.119x | +813.41% |
| 2015-12-31 | CN¥1.44 Billion ≈ $210.71 Million |
CN¥18.77 Million ≈ $2.75 Million |
0.013x | -70.59% |
| 2014-12-31 | CN¥1.48 Billion ≈ $216.53 Million |
CN¥65.56 Million ≈ $9.59 Million |
0.044x | +62.55% |
| 2013-12-31 | CN¥1.46 Billion ≈ $213.55 Million |
CN¥39.78 Million ≈ $5.82 Million |
0.027x | -63.29% |
| 2012-12-31 | CN¥1.34 Billion ≈ $195.97 Million |
CN¥99.44 Million ≈ $14.55 Million |
0.074x | +48.64% |
| 2011-12-31 | CN¥1.19 Billion ≈ $174.38 Million |
CN¥59.53 Million ≈ $8.71 Million |
0.050x | -28.93% |
| 2010-12-31 | CN¥1.10 Billion ≈ $161.57 Million |
CN¥77.61 Million ≈ $11.36 Million |
0.070x | -42.90% |
| 2009-12-31 | CN¥313.80 Million ≈ $45.92 Million |
CN¥38.63 Million ≈ $5.65 Million |
0.123x | -52.47% |
| 2008-12-31 | CN¥221.03 Million ≈ $32.34 Million |
CN¥57.24 Million ≈ $8.38 Million |
0.259x | +524.40% |
| 2007-12-31 | CN¥184.68 Million ≈ $27.02 Million |
CN¥7.66 Million ≈ $1.12 Million |
0.041x | -- |
About Huaren Pharmaceutical Co Ltd
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therape… Read more